EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 56 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR FDA Approves Safety Labelling Changes Regarding DPD Deficiency for Fluorouracil Injection... April 19, 2024 Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast December 2, 2020 FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour November 26, 2021 Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with... August 28, 2023 Load more HOT NEWS Teclistamab Results in a High Rate of Deep and Durable Response... New Treatment Combinations Slow Progression of Prostate Cancer and Stomach and... ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay...
